Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Langenbecks Arch Surg ; 408(1): 103, 2023 Feb 24.
Article in English | MEDLINE | ID: mdl-36826595

ABSTRACT

PURPOSE: The association between sarcopenia of kidney transplant recipients and outcome after kidney transplantation (KT) has not yet been fully understood and is still considered controversial. The aim of our study was to analyze the impact of pre-transplant sarcopenia on graft function, postoperative complication rates, and survival of the patients after renal transplantation. METHODS: In this retrospective single-center study, all patients who underwent KT (01/2013-12/2017) were included. Demographic data, rejection rates, delayed graft function, and graft and patient survival rates were analyzed. Sarcopenia was measured in computed tomography images by the sex-adjusted Hounsfield unit average calculation (HUAC). RESULTS: During the study period, 111 single KTs (38 women and 73 men) were performed. Living donor kidney transplants were performed in 48.6%. In total, 32.4% patients had sarcopenia. Sarcopenic patients were significantly older (59.6 years vs. 49.8 years; p < 0.001), had a higher body mass index (BMI = 27.6 kg/m2 vs. 25.0 kg/m2; p = 0.002), and were more likely to receive deceased donor kidneys (72.2% vs. 41.3%; p = 0.002). Interestingly, 3 years after KT, the creatinine serum levels were significantly higher (2.0 mg/dl vs. 1.5 mg/dl; p = 0.001), whereas eGFR (39.9 ml/min vs. 53.4 ml/min; p = 0.001) and graft survival were significantly lower (p = 0.004) in sarcopenic transplant recipients. Sarcopenic patients stayed in hospital significantly longer postoperatively than those who were non-sarcopenic. CONCLUSIONS: At the time of kidney transplantation, sarcopenia was found to predict reduced long-term graft function and diminished graft survival after KT. The early identification of sarcopenic patients can not only enable an optimized selection of recipients, but also the initiation of pre-habilitation programs during the waiting period.


Subject(s)
Kidney Transplantation , Sarcopenia , Male , Humans , Female , Kidney Transplantation/adverse effects , Graft Survival , Retrospective Studies , Transplant Recipients , Tissue Donors , Graft Rejection
2.
Clin Exp Immunol ; 193(2): 241-254, 2018 08.
Article in English | MEDLINE | ID: mdl-29679490

ABSTRACT

Patients with recurrent miscarriage (RM) show up-regulated cytotoxic natural killer (NK) cells that are suspected to play a causal role in abortion. In the present study, we investigated counter-regulating inhibitory mechanisms and compared the results in RM patients with those of healthy controls (HC), patients with end-stage renal disease (ESRD) and kidney transplant recipients late post-transplant (TX). NK, NK T and T cell subsets were analysed in the peripheral blood of 31 RM, 14 female ESRD and nine female TX patients as well as 21 female HC using eight-colour fluorescence flow cytometry. Compared with HC, RM patients showed significantly higher absolute numbers of CD56+ NK cells co-expressing the phenotype interferon (IFN)-γR+ , IL-4+ , transforming growth factor (TGF)-ß+ , IL-4+ human leucocyte antigen D-related (HLA-DR)+ , TGF-ß+ HLA-DR+ , IL-4+ TGF-ß+ , IL-4+ TGF-ß- , IFN-γ+ and/or IL-10- IFN-γ+ (all P ≤ 0·01), more IL-17+ CD56bright (P = 0·028) NK cells and more CD56dim CD16+ NK cells co-expressing IFN-γR, IFN-γ, IL-4 and/or TGF-ß (all P ≤ 0·01). When the same cell subsets were analysed in ESRD or TX patients, cytokine-producing NK cell subsets were not significantly different from those of HC. RM patients showed significantly higher absolute numbers of CD158a+ , CD158b+ , CD158a- CD158e+ (all P < 0·05), NKG2D+ NKG2A+ , NKG2D + NKG2A- , NKG2D+ and/or NKG2A+ (all P ≤ 0·01) CD56+ NK cells and higher CD158a+ , CD158b+ (all P < 0·05), NKG2D+ and/or NKG2A+ (all P < 0·01) CD56dim+ CD16+ NK cells than HC. In contrast, ESRD patients had normal and TX recipients had lower CD158a+ and NKG2D+ NKG2A- CD56+ NK cells and lower CD158a+ CD56dim+ CD16+ NK cells (all P < 0·05) than HC. RM patients have abnormally high circulating NK cells expressing inhibitory cytokines and inhibitory surface receptors which might contribute to the pathogenesis of RM.


Subject(s)
Abortion, Habitual/immunology , Graft Rejection/immunology , Kidney Transplantation , Killer Cells, Natural/immunology , Lymphocyte Subsets/immunology , Receptors, Natural Killer Cell/metabolism , Adult , Aged , Cytokines/metabolism , Female , Flow Cytometry , Humans , Immunophenotyping , Middle Aged , Pregnancy , Transplant Recipients , Young Adult
3.
Acta Neurol Scand ; 131(3): 176-86, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25312985

ABSTRACT

OBJECTIVES: Due to demographic change and high incidence of epilepsy in elderly, the number of elderly with epilepsies is increasing. However, only few studies investigated the impact of epilepsy on quality of life (QoL). We investigated how epilepsy affects different aspects of QoL dependent on the age of the patients and the age of onset of epilepsy. MATERIALS AND METHODS: In a multicenter, cross-sectional study, three patient groups were recruited from five centers: Group A1: 45 elderly (≥65 years.) with late onset of epilepsy (≥65 years), group A2: 51 elderly (≥65 years.) with early-onset, long-lasting epilepsy (≤50 years), group B: 41 young adults (≤50 years) with epilepsy. Statistical analysis of differences between groups was performed using generalized linear models. RESULTS: Elderly with late-onset epilepsy (group A1) had a significantly lower seizure frequency, were treated with less anti-epileptic drugs (AEDs), and reported a better tolerability of AED treatment, but had more comorbidities compared with groups A2 and B. After adjusting for seizure frequency, tolerability of AEDs and comorbidity, young adults (group B) reported the highest overall QoL, whereas patients of group A1 and A2 did not differ significantly. Epilepsy-related fears, especially fears of stigmatization, were significantly higher in elderly with long-lasting epilepsy compared with groups A1 and B. CONCLUSION: Seizure-related variables, tolerability of AEDs and comorbidity have a stronger impact on QoL and on restrictions due to epilepsy than age, age at onset of epilepsy or duration of epilepsy. However, some results indicate group-specific patterns of impairment and epilepsy-related fears.


Subject(s)
Anticonvulsants/therapeutic use , Epilepsy/drug therapy , Epilepsy/psychology , Fear , Quality of Life , Aged , Aged, 80 and over , Comorbidity , Cross-Sectional Studies , Female , Humans , Male , Middle Aged
4.
Dtsch Med Wochenschr ; 134(45): 2274-7, 2009 Nov.
Article in German | MEDLINE | ID: mdl-19876801

ABSTRACT

HISTORY: A 22-year-old female without relevant underlying medical conditions presented with an acute onset of dysphasia. Her blood pressure was found to be 190/90 mm Hg. INVESTIGATIONS: Physical examination revealed left-sided hemiplegia and Broca's aphasia. A blood count showed anemia and thrombocytopenia. Cranial CT and MR imaging revealed small hypodense periventricular and cerebellar lesions. Mitral valve insufficiency and bilateral pleural effusion were found in echocardiography and chest x-ray, respectively. DIAGNOSIS, TREATMENT AND COURSE: A hypertensive emergency with cerebral and cardiac end-organ lesions was diagnosed. Blood pressure could not be controlled despite combination therapy of intravenous antihypertensive drugs. A full check-up for secondary hypertension revealed systemic lupus erythematosus (SLE) and catastrophic antiphospholipid syndrome (APS). Treatment of SLE/APS resulted in considerable improvement of blood pressure. CONCLUSION: After ruling out frequent causes of hypertensive emergencies, such as insufficient adherence to drug therapy of primary hypertension, or secondary hypertension caused by renoparenchymal disease or renal artery stenosis, vasculitis or systemic diseases like SLE should be considered.


Subject(s)
Hypertension/etiology , Lupus Erythematosus, Systemic/diagnosis , Adrenal Cortex Hormones/therapeutic use , Antihypertensive Agents , Biopsy , Blood Pressure/drug effects , Brain/pathology , Emergencies , Female , Humans , Hypertension/drug therapy , Hypertension/pathology , Immunosuppressive Agents/therapeutic use , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/pathology , Magnetic Resonance Imaging , Muscle Hypertonia/etiology , Muscle Hypertonia/pathology , Myocardium/pathology , Plasmapheresis , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...